No Data
Spot information for individual stocks (1)
Oncoris B <4588.T> is steady. Obtained business license for manufacturing and selling regenerative medical products. Showa Vacuum <6384.T> reached its highest price since last year. The consolidated operating profit Financial Estimates for the fiscal year ending March 2025 have been raised. Disco <6146.T> is performing well. For the first quarter of the fiscal year ending March 2026 (April to June), the consolidated operating profit Financial Estimates were 23.8 billion yen (a decrease of 28.7% compared to the previous period), but there is a growing view that this is conservative. ☆The above article contains unverified information. Provided by Wealth Advisor Corp.
Strong performance, with continued expectations for U.S.-Japan tariff negotiations.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to have a solid development. Yesterday, on the 17th, in the U.S. stock market, the Dow Inc fell sharply by $527.16 (-1.33%) to $39,142.23, marking a significant three-day decline. The decline of the managed healthcare company, UnitedHealth, weighed heavily on the market. Additionally, concerns have intensified that the independence of the Federal Reserve (FRB) may be undermined due to President Trump's Social Media Post, leading to an acceleration of selling.
CNS, Fanpep, and others.
＜4076＞CNS has revised its forecast, and the end-of-term Dividends per share is set at 75.00 yen, up from 49.00 yen (including a 40th Anniversary commemorative Dividends of 49.00 yen). ＜4258＞Amiya has finished the acquisition of its own shares. ＜4588＞OncoRis has obtained a business license for regenerative medicine product manufacturing and sales. ＜4881＞FanPep has started administering an allergy Vaccine to subjects in its clinical trials. ＜4890＞Tsubota Lab has commenced a domestic Phase II trial of TLM-003 targeted at myopia patients.
Individual stock information.
Oncolys BioPharma's tumor lysis adenovirus "OBP-301", for which the company had filed a patent application, has received patent examination approval domestically in Japan. The patent term is until May 2040. There are plans to submit approval applications for "OBP-301" as a regenerative medical product for esophageal cancer treatment within the current December period. After a morning rise, the stock price showed a decline. Basis's stock has significantly increased, updating last year's high. Every year on June 30 and December 31.
Oncolys BioPharma: Business briefing materials
Soft trends and a decline in U.S. stocks are burdensome, but there may be a firm bottom in the market.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to experience a sluggish development. In yesterday's U.S. Stock market on the 26th, the Dow Inc fell by 132.71 points (-0.31%) to 42,454.79, reversing a four-day trend. The uncertainty surrounding 'reciprocal tariffs', strengthened semiconductor regulations in China, and the rise in long-term interest rates following the warning from the St. Louis Fed President about the risks of persistent inflation all weighed on stock prices. Today, selling is likely to dominate the Emerging Markets.
